Results 11 to 20 of about 588,459 (256)

Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting

Frontiers in Immunology, 2023
Cancerous B cells are almost indistinguishable from their non-malignant counterparts regarding their surface antigen expression. Accordingly, the challenge to be faced consists in elimination of the malignant B cell population while maintaining a ...
Katrin Schoenfeld, Julia Harwardt, Jan Habermann, Adrian Elter, Harald Kolmar, Harald Kolmar   +5 more
doaj   +1 more source

Antibody–Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned [PDF]

Clinical Pharmacokinetics, 2017
Antibody-drug conjugates are an emerging class of biopharmaceuticals changing the landscape of targeted chemotherapy. These conjugates combine the target specificity of monoclonal antibodies with the anti-cancer activity of small-molecule therapeutics. Several antibody-drug conjugates have received approval for the treatment of various types of cancer ...
Hazem E. Hassan, Hazem E. Hassan, Tamer E. Fandy, Hongbing Wang, William D. Hedrich, Hossam M. Ashour, Hossam M. Ashour   +6 more
openaire   +3 more sources

Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate

Pharmaceutics, 2022
As one of the major therapeutic options for cancer treatment, chemotherapy has limited selectivity against cancer cells. Consequently, this therapeutic strategy offers a small therapeutic window with potentially high toxicity and thus limited efficacy of
Rotimi Sheyi, B. G. de la Torre, F. Albericio   +2 more
semanticscholar   +1 more source

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma

Blood, 2022
In this Blood Spotlight, Calabretta and colleagues describe the mechanism of action of loncastuximab tesirine, an anti-CD19 antibody-drug conjugate. They discuss data from the first phase 1 and 2 trials of the drug in patients with relapsed or refractory
Eleonora Calabretta, M. Hamadani, C. Carlo-Stella   +2 more
semanticscholar   +1 more source

Anti-VEGFR2 F(ab′)2 drug conjugate promotes renal accumulation and glomerular repair in diabetic nephropathy

Nature Communications, 2023
Poor renal distribution of antibody-based drugs is the key factor contributing to low treatment efficiency for renal diseases and side effects. Here, we prepare F(ab′)2 fragmented vascular endothelial growth factor receptor 2 antibody (anti-VEGFR2 (F(ab′)
Di Liu, Yanling Song, Hui Chen, Yuchan You, Luwen Zhu, Jucong Zhang, Xinyi Xu, Jiahao Hu, Xiajie Huang, Xiaochuan Wu, Xiaoling Xu, Saiping Jiang, Yongzhong Du   +12 more
doaj   +1 more source

Efficacy and Safety of ABBV‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double‐Blind, Active‐Controlled Proof‐of‐Concept Phase IIa Trial

Arthritis & Rheumatology, 2022
To assess the efficacy and safety of ABBV‐3373, a novel antibody–drug conjugate (ADC) composed of the anti–tumor necrosis factor (anti‐TNF) monoclonal antibody adalimumab linked to a glucocorticoid receptor modulator (GRM), compared to adalimumab, in ...
F. Buttgereit, J. Aelion, B. Rojkovich, A. Zubrzycka-Sienkiewicz, Su Chen, Yang Yang, D. Arikan, Ronilda R. D’Cunha, Yinuo Pang, H. Kupper, T. Radstake, H. Amital   +11 more
semanticscholar   +1 more source

Overcoming Resistance to Anti-nectin-4 Antibody-Drug Conjugate.

Molecular Cancer Therapeutics, 2022
Antibody-drug conjugates (ADCs) represent a fast-growing drug class in oncology. However, ADCs are associated with resistance, and therapies able to overcome it are of utmost importance.
O. Cabaud, Ludovic G M Berger, E. Crompot, J. Adélaide, P. Finetti, S. Garnier, A. Guille, N. Carbuccia, A. Farina, Emilie Agavnian, M. Chaffanet, A. Gonçalves, E. Charafe-Jauffret, E. Mamessier, Daniel Birmbaum, F. Bertucci, Marc Lopez   +16 more
semanticscholar   +1 more source

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

Molecular Cancer Therapeutics, 2021
Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors and correlates with poor prognosis. We developed the novel TROP2-directed antibody–drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd, DS-1062a), with a ...
D. Okajima, Satoru Yasuda, T. Maejima, Tsuyoshi Karibe, Ken Sakurai, T. Aida, Tadashi Toki, J. Yamaguchi, Michiko Kitamura, Reiko Kamei, Tomomichi Fujitani, T. Honda, T. Shibutani, Sumie Muramatsu, T. Nakada, R. Goto, S. Takahashi, M. Yamaguchi, H. Hamada, Yutaka Noguchi, M. Murakami, Yuki Abe, T. Agatsuma   +22 more
semanticscholar   +1 more source

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Scientific Reports, 2021
A wide range of diseases have been shown to be influenced by the accumulation of senescent cells, from fibrosis to diabetes, cancer, Alzheimer’s and other age-related pathologies.
M. Poblocka, A. Bassey, V. Smith, M. Falcicchio, A. S. Manso, M. Althubiti, Xiaobo Sheng, A. Kyle, R. Barber, M. Frigerio, S. Macip   +10 more
semanticscholar   +1 more source

Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency

Frontiers in Pharmacology, 2021
The development of antibody-drug conjugates (ADCs) has significantly been advanced in the past decade given the improvement of payloads, linkers and conjugation methods.
Dian Su, Donglu Zhang
semanticscholar   +1 more source